サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1375902

冠動脈ステントの市場規模、シェア、動向分析レポート：製品別、地域別、セグメント予測、2023年～2030年

Coronary Stents Market Size, Share & Trends Analysis Report By Product (Bare Metal Stents (BMS), Drug Eluting Stents (DES), Bioresorbable Vascular Scaffold), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 110 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
冠動脈ステントの市場規模、シェア、動向分析レポート：製品別、地域別、セグメント予測、2023年～2030年
出版日: 2023年10月09日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

冠動脈ステント市場の成長と動向：

Grand View Research社の最新レポートによると、世界の冠動脈ステント市場規模は2030年までに121億米ドルに達する見込みです。

2023年から2030年までのCAGRは3.1%で市場は拡大する見込みです。低侵襲手術や経皮的冠動脈インターベンション（PCI）手技の採用が増加していることが、今後数年間の市場を牽引すると見られています。例えば、The Korean Journal of Thoracic and Cardiovascular Surgeryによると、2016年の冠動脈疾患（CAD）に対するPCIの割合は78％、国別のPCI割合は96％で、世界平均を大きく上回っています。その結果、CAD罹患率のかつてない増加とともに、これらのCAD患者に対して行われるPCIの割合が増加し、効果的な冠動脈ステント技術に対する需要が高まると予想されます。

技術の進歩と第2世代の薬剤溶出ステントの発売が、さらに成長を促進しています。例えば、Abbott Laboratories LaboratoriesのXIENCE Sierraは、2018年5月に米国でCTO適応で承認された最初のDESとなっています。メドトロニックも2019年初めにこれに続き、CTO適応における同社のResoluteシリーズのDESの使用についてFDAの承認を取得しました。さらに、多くの企業が最近米国で冠動脈ステントシステムの新バージョンを発売しており、特にボストン・サイエンティフィックのシナジー・メガトロンは2021年1月に、アボット・ラボラトリーズ・ラボラトリーズのXIENCE Skypointは2021年6月に発売されました。

COVID-19の世界的大流行は冠動脈ステント市場に悪影響を与えました。世界中の医師会のガイドラインによると、手技の延期は主に適格な患者に対する緊急性の低い手技や選択的な手技に影響を与えました。例えばACC（米国心臓病学会）の2020年ガイダンスでは、COVID-19流行のピーク時にはCTOインターベンションやサーベイランス血管造影のような緊急性のない手技の延期を推奨していました。これらのガイドラインは世界中で医師の治療決定に影響を与えています。さらに、欧州心臓病学会の勧告によると、すべての緊急および緊急PCI手技（STEMI、高または中リスクのNSTEMI、心原性ショック、不安定狭心症の治療）は、パンデミックのピーク時およびその後のCOVID-19の再流行時にも継続されるべきであり、一方、選択的PCI手技（CTOインターベンションまたはNYHA II症状の治療）のみ延期されるべきです。

さらに、COVID-19パンデミックからの冠動脈ステント市場の回復は、緊急PCI手技の継続的な実施と非選択的手技を実施するための稼働率の上昇によって助長されると予想されます。

冠動脈ステント市場は、一般の公的機関であるメディケア＆メディケイドサービスセンター（CMS）や民間の支払者によって提供される償還保険によって牽引されています。頸動脈ステント留置術の保険適用範囲は、製品やサービスプロバイダーを含む全国的な保険適用範囲決定に基づいています。2020年1月以降、メディケア＆メディケイドサービスセンター（CMS）は、外来手術センター（ASC）で実施される一部の血管形成術およびステント留置術に対する償還を提案し、予測期間中の市場収益を押し上げることが期待されます。

冠動脈ステント市場レポートハイライト

  • 冠動脈ステントデバイスで治療されるPCI手技全体の件数は、高齢化とPCI適格患者数の増加に伴い、新技術と重症病変の治療能力の向上により増加します。
  • 生体吸収性血管足場は、冠動脈疾患の治療において、患者の心臓に一時的に留置されること、3年で分解されるため将来の治療が容易であること、患者の体内で完全に溶解することなど、いくつかの利点があるため、2番目に急成長する分野と予想されます。
  • DESが標準的なBMSよりも優れていることは、良好な臨床試験によって証明されています。その結果、2021年にはDESが市場を独占しています。
  • 北米が冠動脈ステント市場を独占し、2022年には32.6%の最大収益シェアを占め、当面同じ傾向が続くと予測されています。
  • アジア太平洋地域の冠動脈ステント市場は、最も速い成長率を示すと予想されています。この市場は、CADのスクリーニング強化、経済成長、規制の更新、オーストラリアや韓国のような一部の国における注目すべき有益な償還などの追加変数によって牽引されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 冠状動脈ステントの変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 冠動脈ステント市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 冠状動脈ステント：製品推定・動向分析

  • 冠状動脈ステント市場：重要なポイント
  • 冠状動脈ステント市場：動向と市場シェア分析、2022年および2030年
  • ベアメタルステント（BMS）
    • ベアメタルステント
  • 薬剤溶出ステント（DES）
    • 薬剤溶出ステント
  • 生体吸収性血管足場
    • 生体吸収性血管足場市場推計・予測、2018年から2030年まで

第5章 冠状動脈ステント市場：地域推定・動向分析

  • 地域別の見通し
  • 地域別の冠状動脈ステント市場：重要なポイント
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
    • Abbott
    • Medtronic
    • Boston Scientific Corporation
    • Terumo Corporation
    • B Braun Melsungen AG
    • Biotronik
    • Stentys SA
    • MicroPort Scientific Corporation
    • C.R. Bard, Inc.
    • Cook Medical
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America coronary stents market, by country, 2018 - 2030 (USD Million)
  • Table 4 U.S. coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 5 Canada coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 6 Europe coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 7 Europe coronary stents market, by country, 2018 - 2030 (USD Million)
  • Table 8 Germany coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 9 UK coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 10 France coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 11 Italy coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 12 Spain coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 13 Sweden coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 14 Norway coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 15 Denmark coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific coronary stents market, by country, 2018 - 2030 (USD Million)
  • Table 18 Japan coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 19 China coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 20 India coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 21 Australia coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 22 Thailand coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 23 South Korea coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 24 Latin America coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 25 Latin America coronary stents market, by region, 2018 - 2030 (USD Million)
  • Table 26 Brazil coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 27 Mexico coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 28 Argentina coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa coronary stents market, by country, 2018 - 2030 (USD Million)
  • Table 31 South Africa coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 33 UAE coronary stents market, by product, 2018 - 2030 (USD Million)
  • Table 34 Kuwait coronary stents market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Coronary stents: Market outlook
  • Fig. 9 Coronary stents: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Coronary stents market driver impact
  • Fig. 15 Coronary stents market restraint impact
  • Fig. 16 Coronary stents market strategic initiatives analysis
  • Fig. 17 Coronary stents market: Product movement analysis
  • Fig. 18 Coronary stents market: Product outlook and key takeaways
  • Fig. 19 Bare metal stents (BMS) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Drug-eluting stents (DES) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Biodegradable market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Non-Biodegradable market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Bioresorbable vascular scaffold market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global coronary stents market: Regional movement analysis
  • Fig. 25 Global coronary stents market: Regional outlook and key takeaways
  • Fig. 26 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-106-1

Coronary Stents Market Growth & Trends:

The global coronary stents market size is expected to reach USD 12.10 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 3.1% from 2023 to 2030. Increasing adoption of minimally invasive surgeries and Percutaneous Coronary Intervention (PCI) procedures is expected to drive the market in the coming years. For instance, according to The Korean Journal of Thoracic and Cardiovascular Surgery, the proportion of PCI for Coronary Artery Disease (CAD) was 78% in 2016, and the country-specific PCI proportion was 96%, which was significantly higher than the global average. As a result, the unprecedented growth in CAD incidence, along with an increase in the proportion of PCIs done in these CAD patients, is expected to raise demand for an effective coronary stent technology.

Technological advancement and the launch of 2nd generation drug-eluting stents are further fueling the growth. For instance, Abbott Laboratories Laboratories' XIENCE Sierra became the first DES approved for CTO indications in the US in May 2018. Medtronic followed suit in early 2019, obtaining FDA approval for the use of its Resolute range of DES in CTO indications. In addition, many companies have recently launched newer versions of their coronary stent systems in the US, notably Boston Scientific's Synergy Megatron in January 2021 and Abbott Laboratories Laboratories' XIENCE Skypoint in June 2021.

The global COVID-19 pandemic has had a negative impact on the market for coronary stents. According to guidelines from physician societies throughout the world, procedure deferrals primarily impacted less urgent or elective procedures for eligible patients. ACC's ((American College of Cardiology) 2020 guidance, for instance, recommended postponing non-urgent procedures like CTO interventions and surveillance angiography during the peak of the COVID-19 pandemic. These guidelines have influenced physicians' treatment decisions throughout the world. Additionally, according to the European Society of Cardiology recommendations, all emergency and urgent PCI procedures (treatment of STEMI, high or intermediate risk NSTEMI, cardiogenic shock, and unstable angina) should be continued during the peak of the pandemic and in the subsequent resurgence of COVID-19, while only elective PCI procedures (CTO interventions or treatment of NYHA II symptoms) should be deferred.

Moreover, recovery of the coronary stent market from the COVID-19 pandemic is anticipated to be aided by the continuous performance of urgent PCI procedures and an increase in capacity utilization for performing non-elective procedures.

The coronary stent market is driven by reimbursement coverage provided by the general public Center for Medicare & Medicaid Services (CMS) and private payers. The coverage is availed under national coverage determination for carotid artery stenting, including products and service providers. From January 2020, the Centers for Medicare & Medicaid Services (CMS) proposed reimbursement for some angioplasty and stenting procedures performed in the ambulatory surgical centers (ASC), which is expected to boost the market revenue over the forecast period.

Coronary Stents Market Report Highlights:

  • Overall PCI procedure volumes treated with coronary stent devices will rise as the aging population and the PCI-eligible patient population grows, owing to new technologies and increased ability to treat severe lesions
  • The bioresorbable vascular scaffold segment is expected to be the second fastest growing segment due to its several advantages in treating coronary artery disease including temporary placement in the patient heart, ease for future treatments as it degrades over 3 years, and it dissolve completely in the patient body.
  • Favorable clinical trials have demonstrated that DES is better than standard BMS. As a result, in 2021, DES has dominated the market
  • North America dominated the coronary stents market and accounted for the largest revenue share of 32.6% in 2022 and is anticipated to witness the same trend over the foreseeable future.
  • The Asia Pacific market for coronary stents is expected to exhibit the fastest growth rate in terms of revenue generation. This market is driven by some additional variables of enhanced screening for CAD, economic growth, regulatory updates, and notable beneficial reimbursement in some countries such as Australia and South Korea.

Table of Contents

Chapter 1. Methodology & Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Coronary stents Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Coronary Stents Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Coronary stents: Product Estimates & Trend Analysis

  • 4.1. Coronary Stents Market: Key Takeaways
  • 4.2. Coronary Stents Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Bare Metal Stents (BMS)
    • 4.3.1. Bare Metal Stents (BMS) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Drug-Eluting Stents (DES)
    • 4.4.1. Drug-Eluting Stents (DES) market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.4.1.1. Biodegradable
      • 4.4.1.1.1. Biodegradable market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.4.1.2. Non-Biodegradable
      • 4.4.1.2.1. Non-Biodegradable market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Bioresorbable Vascular Scaffold
    • 4.5.1. Bioresorbable vascular scaffold market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 5. Coronary Stents Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Outlook
  • 5.2. Coronary Stents Market by Region: Key Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
    • 6.2.1. Abbott
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Medtronic
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. Boston Scientific Corporation
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Terumo Corporation
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. B Braun Melsungen AG
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. Biotronik
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. Stentys SA
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. MicroPort Scientific Corporation
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. C.R. Bard, Inc.
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives
    • 6.2.10. Cook Medical
      • 6.2.10.1. Company overview
      • 6.2.10.2. Financial performance
      • 6.2.10.3. Product benchmarking
      • 6.2.10.4. Strategic initiatives